Adaptive Biotechnologies Corporation announced that as of January 1, 2025, the new Medicare Clinical Laboratory Fee Schedule includes a payment rate of $2,007 for its clonoSEQ test used for assessing ...
SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of ...
SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback